Skip to main content
. 2020 May 11;158:104899. doi: 10.1016/j.phrs.2020.104899

Table 2.

Severe adverse events (AEs) in patients with SARS-CoV-2 pneumonia receiving remdesivir.

Event Total n = 35 ICU n = 18 IDWn = 17
Reported grade 2−3 AEs
Hypertransaminasemia 15 (42.8 %) 8 (44.4 %) 7 (41.2 %)
Increased total bilirubin levels 7 (20.0 %) 2 (11.1 %) 5 (29.4 %)
Acute kidney injury 8 (22.8 %) 7 (38.8 %) 1 (5.9 %)
Rash 2 (5.7 %) 2 (11.8 %)
Any AE leading to treatment discontinuation 8 (22.8 %) 6 (33.3 %) 2 (11.7 %)